bivalirudin market size forecast and market insight

“Bivalirudin Market Size, Forecast, and Market Insight − 2032” report provides comprehensive insights about Bivalirudin for Heparin Induced Thrombocytopenia (HIT) in the US. A detailed picture of the Bivalirudin for HIT in the United States for the study period 2019 –2032 is provided in this report along with a detailed description of the Bivalirudin for HIT. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Bivalirudin market forecast analysis for HIT in the US, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in HIT.

 Drug Summary

Bivalirudin is an inhibitor of thrombin, an essential factor within the coagulation cascade crucial to thrombus formation, and is used as an anticoagulant. Bivalirudin reversibly binds thrombin, free as well as clot bound, at the catalytic site and the anion-binding exosite, thereby preventing the formation and activation of fibrin, Factor XIIIa, and other coagulation factors. It is administered intravenously. It is indicated for use in patients undergoing percutaneous coronary intervention (PCI), including patients with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS). Its short duration of effect makes it convenient for those with bleeding risks or undergoing additional procedural interventions and needing a rapid cessation of drug effect.

Dosage and administration

The recommended dose of ANGIOMAX is an IV bolus dose of 0.75 mg/kg, followed immediately by an infusion of 1.75 mg/kg/h for the duration of the procedure.

Mechanism of action

Bivalirudin directly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework that stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release. The binding of bivalirudin to thrombin is reversible as thrombin slowly cleaves the bivalirudin-Arg3-Pro4 bond, resulting in the recovery of thrombin active site functions.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Bivalirudin description, mechanism of action, dosage and administration, research and development activities in Heparin Induced Thrombocytopenia (HIT).
• Elaborated details on Bivalirudin regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Bivalirudin research and development activities in HIT across the United States.
• The report also covers the patents information with expiry timeline around Bivalirudin.
• The report contains forecasted sales of Bivalirudin for HIT till 2032.
• Comprehensive coverage of the late-stage emerging therapies for HIT.
• The report also features the SWOT analysis with analyst views for Bivalirudin in HIT.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Bivalirudin Analytical Perspective by DelveInsight

In-depth Bivalirudin Market Assessment

This report provides a detailed market assessment of Bivalirudin for Heparin Induced Thrombocytopenia (HIT) in the United States. This segment of the report provides forecasted sales data from 2025 to 2032.

Bivalirudin Clinical Assessment

The report provides the clinical trials information of Bivalirudin for Heparin Induced Thrombocytopenia (HIT) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Heparin Induced Thrombocytopenia (HIT) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Bivalirudin dominance.
• Other emerging products for HIT are expected to give tough market competition to Bivalirudin and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Bivalirudin in HIT.
• Our in-depth analysis of the forecasted sales data of Bivalirudin from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Bivalirudin in HIT.

Key Questions

• What is the product type, route of administration and mechanism of action of Bivalirudin?
• What is the clinical trial status of the study related to Bivalirudin in Heparin Induced Thrombocytopenia (HIT) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Bivalirudin development?
• What are the key designations that have been granted to Bivalirudin for HIT?
• What is the forecasted market scenario of Bivalirudin for HIT?
• What are the forecasted sales of Bivalirudin in the United States? 
• What are the other emerging products available and how are these giving competition to Bivalirudin for HIT?
•  
• Which are the late-stage emerging therapies under development for the treatment of HIT?